Contraceptive Methods and Informed Consent among Women Receiving Medications with Potential for Adverse Fetal Effects: A Washington, Wyoming, Alaska, Montana, Idaho (WWAMI) Region Study

References

1. 1.↵
   1. Egan BM,
   2. Zhao Y,
   3. Axon RN

   . US trends in prevalence, awareness, treatment, and control of hypertension, 1988–2008. JAMA 2010;303:2043–50.

   OpenUrlCrossRefPubMedWeb of Science
2. 2.↵
   1. Hyre AD,
   2. Muntner P,
   3. Menke A,
   4. Raggi P,
   5. He J

   . Trends in ATP-III-defined high blood cholesterol prevalence, awareness, treatment and control among U.S. adults. Ann Epidemiol 2007;17:548–55.

   OpenUrlCrossRefPubMed
3. 3.↵
   1. Mann D,
   2. Reynolds K,
   3. Smith D,
   4. Muntner P

   . Trends in statin use and low-density lipoprotein cholesterol levels among US adults: impact of the 2001 National Cholesterol Education Program guidelines. Ann Pharmacother 2008;42:1208–15.

   OpenUrlCrossRefPubMedWeb of Science
4. 4.↵
   Centers for Disease Control and Prevention. Diabetes data & trends. Number (in millions) of civilian, non-institutionalized persons with diagnosed diabetes, United States, 1980–2009. Available from: http://www.cdc.gov/diabetes/statistics/prev/national/figpersons.htm. Accessed August 18, 2011.
5. 5.↵
   1. Chobanian AV,
   2. Bakris GL,
   3. Black HR,
   4. et al

   . The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 report. JAMA 2003;289:2560–72.

   OpenUrlCrossRefPubMedWeb of Science
6. 6.↵
   1. Martin U,
   2. Foreman MA,
   3. Travis JC,
   4. Casson D,
   5. Coleman JJ

   . Use of ACE inhibitors and ARBs in hypertensive women of childbearing age. J Clin Pharm Ther 2008;33:507–11.

   OpenUrlPubMed
7. 7.↵
   Centers for Disease Control and Prevention (CDC). Vital signs: prevalence, treatment, and control of high levels of low-density lipoprotein cholesterol–United States, 1999–2002 and 2005–2008. MMWR Morb Mortal Wkly Rep 2011;60:109–14.

   OpenUrlPubMed
8. 8.↵
   Centers for Disease Control and Prevention (CDC). Vital signs: prevalence, treatment, and control of hypertension–United States, 1999–2002 and 2005–2008. MMWR Morb Mortal Wkly Rep 2011;60:103–8.

   OpenUrlPubMed
9. 9.↵
   1. Cooper WO,
   2. Hernandez-Diaz S,
   3. Arbogast PG,
   4. et al

   . Major congenital malformations after first-trimester exposure to ACE inhibitors. N Engl J Med 2006;354:2443–51.

   OpenUrlCrossRefPubMedWeb of Science
10. 10.↵
    1. Quan A

    . Fetopathy associated with exposure to angiotensin converting enzyme inhibitors and angiotensin receptor antagonists. Early Hum Dev 2006;82:23–8.

    OpenUrlCrossRefPubMedWeb of Science
11. 11.↵
    1. Edison RJ,
    2. Muenke M

    . Mechanistic and epidemiologic considerations in the evaluation of adverse birth outcomes following gestational exposure to statins. Am J Med Genet A 2004;131:287–98.

    OpenUrlCrossRefPubMed
12. 12.↵
    1. Edison RJ,
    2. Muenke M

    . Central nervous system and limb anomalies in case reports of first-trimester statin exposure. N Engl J Med 2004;350:1579–82.

    OpenUrlCrossRefPubMedWeb of Science
13. 13.↵
    1. Kazmin A,
    2. Garcia-Bournissen F,
    3. Koren G

    . Risks of statin use during pregnancy: a systematic review. J Obstet Gynaecol Can 2007;29:906–8.

    OpenUrlPubMed
14. 14.↵
    1. Bowen ME,
    2. Ray WA,
    3. Arbogast PG,
    4. Ding H,
    5. Cooper WO

    . Increasing exposure to angiotensin-converting enzyme inhibitors in pregnancy. Am J Obstet Gynecol 2008;198:291.e1–5.

    OpenUrlPubMed
15. 15.↵
    1. Lee C,
    2. Force RW,
    3. Pugmire BA,
    4. Owens CT

    . Use of ACE-inhibitors, angiotensin II receptor blockers, and statins in women of childbearing age. Pharmacotherapy 2008;28:72e.

    OpenUrl
16. 16.↵
    1. Schwarz EB,
    2. Longo LS,
    3. Zhao X,
    4. Stone RA,
    5. Cunningham F,
    6. Good CB

    . Provision of potentially teratogenic medications to female veterans of childbearing age. Med Care 2010;48:834–42.

    OpenUrlCrossRefPubMedWeb of Science
17. 17.↵
    1. Schwarz EB,
    2. Postlethwaite DA,
    3. Hung YY,
    4. Armstrong MA

    . Documentation of contraception and pregnancy when prescribing potentially teratogenic medications for reproductive-age women. Ann Intern Med 2007;147:370–6.

    OpenUrlCrossRefPubMedWeb of Science
18. 18.↵
    1. Eisenberg DL,
    2. Stika C,
    3. Desai A,
    4. Baker D,
    5. Yost KJ

    . Providing contraception for women taking potentially teratogenic medications: a survey of internal medicine physicians' knowledge, attitudes and barriers. J Gen Intern Med 2010;25:291–7.

    OpenUrlCrossRefPubMed
19. 19.↵
    1. Morrical-Kline KA,
    2. Walton AM,
    3. Guildenbecher TM

    . Teratogen use in women of childbearing potential: an intervention study. J Am Board Fam Med 2011;24:262–71.

    OpenUrlAbstract/FREE Full Text
20. 20.↵
    1. Schwarz EB,
    2. Maselli J,
    3. Norton M,
    4. Gonzales R

    . Prescription of teratogenic medications in United States ambulatory practices. Am J Med 2005;118:1240–9.

    OpenUrlCrossRefPubMed
21. 21.↵
    1. Schwarz EB,
    2. Santucci A,
    3. Borrero S,
    4. Akers AY,
    5. Nikolajski C,
    6. Gold MA

    . Perspectives of primary care clinicians on teratogenic risk counseling. Birth Defects Res A Clin Mol Teratol 2009;85:858–63.

    OpenUrlCrossRefPubMed
22. 22.↵
    1. Santucci AK,
    2. Gold MA,
    3. Akers AY,
    4. Borrero S,
    5. Schwarz EB

    . Women's perspectives on counseling about risks for medication-induced birth defects. Birth Defects Res A Clin Mol Teratol 2009;88:64–9.

    OpenUrl
23. 23.↵
    1. Lohr PA,
    2. Schwarz EB,
    3. Gladstein JE,
    4. Nelson AL

    . Provision of contraceptive counseling by internal medicine residents. J Womens Health (Larchmt) 2009;18:127–31.

    OpenUrlPubMed
24. 24.↵
    1. Weisman CS,
    2. Maccannon DS,
    3. Henderson JT,
    4. Shortridge E,
    5. Orso CL

    . Contraceptive counseling in managed care: preventing unintended pregnancy in adults. Womens Health Issues 2002;12:79–95.

    OpenUrlPubMed
25. 25.↵
    1. Steinkellner A,
    2. Chen W,
    3. Denison SE

    . Adherence to oral contraception in women on Category X medications. Am J Med 2010;123:929–34 e1.

    OpenUrlPubMed
26. 26.↵
    1. Darden PM,
    2. Ector W,
    3. Moran C,
    4. Quattlebaum TG

    . Comparison of continuity in a resident versus private practice. Pediatrics 2001;108:1263–8.

    OpenUrlAbstract/FREE Full Text
27. 27.↵
    1. Gallagher TH,
    2. Waterman AD,
    3. Ebers AG,
    4. Fraser VJ,
    5. Levinson W

    . Patients' and physicians' attitudes regarding the disclosure of medical errors. JAMA 2003;289:1001–7.

    OpenUrlCrossRefPubMedWeb of Science
28. 28.↵
    1. Mosher WD,
    2. Jones J

    . Use of contraception in the United States: 1982–2008. Vital Health Stat 23. 2010;(29):1–44.
29. 29.↵
    1. Schwarz EB,
    2. Postlethwaite D,
    3. Hung YY,
    4. Lantzman E,
    5. Armstrong MA,
    6. Horberg MA

    . Provision of contraceptive services to women with diabetes mellitus. J Gen Intern Med 2012;27:196–201.

    OpenUrlPubMed